Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Hospitals & Diagnostics
    • IHH unable to proceed...

    IHH unable to proceed with Fortis open offer after SC status quo on deal

    Farhat NasimWritten by Farhat Nasim Published On 2018-12-19T09:35:08+05:30  |  Updated On 19 Dec 2018 9:35 AM IST
    IHH unable to proceed with Fortis open offer after SC status quo on deal

    The open offer by Fortis for an additional 26 per cent stake was scheduled to commence on December 18 and close on January 1, 2019, entailing a total sum of Rs 3,300 crore.




    New Delhi: Malaysia’s IHH Healthcare Monday said it will not be able to proceed with the open offer for Fortis Healthcare for the time being, following the Supreme Court order to put on hold sale of controlling stake in the Indian hospital chain.





    In a regulatory filing, IHH Healthcare, however, said the apex court’s order does not impact acquisition of 31.1 per cent stake in Fortis for RS 4,000 crore, which was completed on November 13.


    The Board of Directors of IHH wishes to inform that the Supreme Court of India had on December 14, 2018, passed an order directing “status quo with regard to the sale of the controlling stake in Fortis Healthcare to Malaysian IHH Healthcare Berhad be maintained”, it said in the filing.


    “In light of the order, NTK and the PACs (persons acting in concert) will not be able to proceed with the Fortis open offer for the time being until further order(s)/ clarification(s)/ direction(s) are issued by the Supreme Court of India and/or the Securities and Exchange Board of India (SEBI),” the company said.


    The open offer for an additional 26 per cent stake was scheduled to commence on December 18 and close on January 1, 2019, entailing a total sum of Rs 3,300 crore.


    Last week, the apex court had ordered status quo with regard to the sale of controlling stakes of Fortis Healthcare while hearing a plea of Japanese firm Daiichi Sankyo, which is seeking to recover Rs 3,500 crore, awarded to it by a Singapore tribunal in its case against the erstwhile promoters of the healthcare chain, Malvinder Singh and Shivinder Singh.


    IHH further said the court order does not impact the subscription of Fortis shares resulting in IHH through NTK, owning 31.1 per cent of the expanded voting share capital of Fortis.


    In July this year, IHH had pipped rival Manipal-TPG combine to clinch a Rs 4,000-crore deal to acquire 31.1 per cent stake in Fortis.


    On the way forward, IHH said it is in the process of evaluating the Supreme Court order and “seeking appropriate legal advice on this matter and will subsequently decide on the future course of action”.


    Also Read: Major Setback to Fortis: SC stops sale process to IHH

    Daiichi SankyoFortisFortis HealthcareFortis sharesIHH HealthcareIndiaMalvinder SinghShivinder SinghSupreme Court
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok